The American Society of Peritoneal Surface Malignancies Evaluation of HIPEC with Mitomycin C Versus Oxaliplatin in 539 Patients with Colon Cancer Undergoing a Complete Cytoreductive Surgery

被引：126

作者：

Prada-Villaverde, Arancha ^{[1
]}

Esquivel, Jesus ^{[2
]}

Lowy, Andrew M. ^{[3
]}

Markman, Maurie ^{[4
]}

Chua, Terence ^{[5
]}

Pelz, Joerg ^{[6
]}

Baratti, Dario ^{[7
]}

Baumgartner, Joel M. ^{[3
]}

Berri, Richard ^{[8
]}

Bretcha-Boix, Pedro ^{[9
]}

Deraco, Marcello ^{[7
]}

Flores-Ayala, Guillermo ^{[10
]}

Glehen, Olivier ^{[11
]}

Gomez-Portilla, Alberto ^{[12
]}

Gonzalez-Moreno, Santiago ^{[13
]}

Goodman, Martin ^{[14
]}

Halkia, Evgenia ^{[15
]}

Kusamura, Shigeki ^{[7
]}

Moller, Mecker ^{[16
]}

Passot, Guillaume ^{[11
]}

Pocard, Marc ^{[17
]}

Salti, George ^{[18
]}

Sardi, Armando ^{[19
]}

Senthil, Maheswari ^{[20
]}

Spiliotis, John ^{[15
]}

Torres-Melero, Juan ^{[21
]}

Turaga, Kiran ^{[22
]}

Trout, Richard ^{[23
]}

机构：

[1] Hosp Infanta Cristina, Deaprtment Gen Surg, Cordoba, Spain

[2] Canc Treatment Ctr Amer, Dept Surg Oncol, Philadelphia, PA USA

[3] Univ Calif San Diego, Div Surg Oncol, Moores Canc Ctr, San Diego, CA 92103 USA

[4] Canc Treatment Ctr Amer, Dept Med Oncol, Philadelphia, PA USA

[5] St George Hosp, Hepatobiliary & Surg Oncol Unit, Sydney, NSW, Australia

[6] Univ Wurzburg, Dept Surg, D-97070 Wurzburg, Germany

[7] Natl Canc Inst, Dept Surg, I-20133 Milan, Italy

[8] St Johns Hosp, Dept Surg Oncol, Detroit, MI USA

[9] Hosp San Jaime, Gen Surg Serv, Alicante, Spain

[10] Inst Jalisciense Cancerol, Dept Surg Oncol, Guadalajara, Jalisco, Mexico

[11] Ctr Hosp Lyon Sud, Dept Surg Oncol, F-69310 Pierre Benite, France

[12] San Jose Hosp, Dept Surg, Vitoria, Spain

[13] MD Anderson Canc Ctr, Dept Surg Oncol, Madrid, Spain

[14] Tufts Med Ctr, Dept Surg Oncol, Boston, MA USA

[15] Metaxa Canc Mem Hosp, Dept Gynecol, Piraeus, Greece

[16] Univ Miami, Dept Surg Oncol, Miami, FL USA

[17] Hosp Lariboisiere, Dept Surg, Paris, France

[18] Univ Illinois, Dept Surg Oncol, Champaign, IL 61820 USA

[19] Mercy Med Ctr, Dept Surg Oncol, Baltimore, MD USA

[20] Loma Linda Univ, Med Ctr, Dept Surg Oncol, Loma Linda, CA 92350 USA

[21] Hosp Torrecardenas, Dept Surg Oncol, Almeria, Spain

[22] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA

[23] Rutgers State Univ, Dept Stat, New Brunswick, NJ 08903 USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2014年 / 110卷 / 07期

关键词：

hyperthermic intraperitoneal chemotherapy (HIPEC); cytoreductive surgery; colorectal cancer with peritoneal carcinomatosis; DISEASE SEVERITY SCORE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; CARCINOMATOSIS;

D O I：

10.1002/jso.23728

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery. MethodsThe American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS). ResultsMedian overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P=0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P=0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P=0.427). ConclusionThese data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Propsective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin. J. Surg. Oncol. 2014 110:779-785. (c) 2014 Wiley Periodicals, Inc.

引用

页码：779 / 785

页数：7

共 15 条

[1] Peritoneal Carcinomatosis: Cytoreductive Surgery and HIPEC-Overview and Basics [J].

Bruecher, Bjoern L. D. M. ;

Piso, Pompiliu ;

Verwaal, Vic ;

Esquivel, Jesus ;

Derraco, Marcello ;

Yonemura, Yutaka ;

Gonzalez-Moreno, Santiago ;

Pelz, Joerg ;

Koenigsrainer, Alfred ;

Stroehlein, Michael ;

Levine, Edward A. ;

Morris, David ;

Bartlett, David ;

Glehen, Olivier ;

Garofalo, Alfredo ;

Nissan, Aviram .

CANCER INVESTIGATION, 2012, 30 (03) :209-224

[2] Summary of current therapeutic options for peritoneal metastases from colorectal cancer [J].

Chua, Terence C. ;

Esquivel, Jesus ;

Pelz, Joerg O. W. ;

Morris, David L. .

JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (06) :566-573

[3] Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study [J].

Chua, Terence C. ;

Morris, David L. ;

Saxena, Akshat ;

Esquivel, Jesus ;

Liauw, Winston ;

Doerfer, Joerg ;

Germer, Christoph-Thomas ;

Kerscher, Alexander G. ;

Pelz, Joerg O. W. .

ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (06) :1560-1567

[4] Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy [J].

Chua, Terence C. ;

Morris, David L. ;

Esquivel, Jesus .

ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (05) :1330-1336

[5] Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo [J].

Cohen, Mark S. ;

Al-kasspooles, Mazin F. ;

Williamson, Stephen K. ;

Henry, David ;

Broward, Melinda ;

Roby, Katherine F. .

ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (01) :296-303

[6] Current Status and Future Directions in the Treatment of Peritoneal Dissemination from Colorectal Carcinoma [J].

Elias, Dominique ;

Quenet, Francois ;

Goere, Diane .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 21 (04) :611-+

[7] The American Society of Peritoneal Surface Malignancies (ASPSM) [J].

Esquivel, Jesus ;

Stojadinovic, Alexander ;

Levine, Edward A. .

ANNALS OF SURGICAL ONCOLOGY, 2011, 18 :S218-S219

[8] Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan, and Korea [J].

Esquivel, Jesus .

CANCER JOURNAL, 2009, 15 (03) :249-254

[9] KRAS Status in Patients With Colorectal Cancer Peritoneal Carcinomatosis and Its Impact on Outcome [J].

Gillern, Suzanne M. ;

Chua, Terence C. ;

Stojadinovic, Alexander ;

Esquivel, Jesus .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (05) :456-460

[10] Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin [J].

Pelz, Joerg O. W. ;

Chua, Terence C. ;

Esquivel, Jesus ;

Stojadinovic, Alexander ;

Doerfer, Joerg ;

Morris, David L. ;

Maeder, Uwe ;

Germer, Christoph-Thomas ;

Kerscher, Alexander G. .

BMC CANCER, 2010, 10

← 1 2 →